ketoconazole has been researched along with Inflammatory Response Syndrome, Systemic in 1 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baue, AE | 1 |
| Durham, RM | 1 |
| Mazuski, JE | 1 |
1 review available for ketoconazole and Inflammatory Response Syndrome, Systemic
| Article | Year |
|---|---|
Clinical trials of new and novel therapeutic agents.
Topics: Antithrombin III; Clinical Trials as Topic; Combined Modality Therapy; Critical Care; Glucagon; Grow | 1996 |